Noxopharm Limited
(ASX:NOX) has announced it entered into a research agreement with the University of Hong Kong to conduct a brain cancer study.
Noxopharm’s study aims to treat both primary and secondary brain cancer cells, in adults and children.
The cancer treatment company says it will collaborate with the University, testing the use of the drug idronoxil (active ingredient NOX66) in treating brain disease.
It comes after the company made a recent breakthrough in getting the drug, idronoxil, to cross the blood-brain barrier and enter the brain at high levels, as it demonstrated in rats.
Noxopharm says only five of the 100 plus chemotherapy drugs available to oncologists, cross the blood-brain barrier - and those five drugs form the backbone of chemotherapy for malignant brain cancers.
